Synonym
NT-157; NT 157; NT157.
IUPAC/Chemical Name
(2E)-3-(3-Bromo-4,5-dihydroxyphenyl)-N-[(3,4,5-trihydroxyphenyl)methyl]-2-propenethioamide
InChi Key
NIPUPOUEGOSAAO-OWOJBTEDSA-N
InChi Code
InChI=1S/C16H14BrNO5S/c17-10-3-8(4-11(19)15(10)22)1-2-14(24)18-7-9-5-12(20)16(23)13(21)6-9/h1-6,19-23H,7H2,(H,18,24)/b2-1+
SMILES Code
S=C(NCC1=CC(O)=C(O)C(O)=C1)/C=C/C2=CC(O)=C(O)C(Br)=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
412.25
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Rampias T, Favicchio R, Stebbing J, Giamas G. Targeting tumor-stroma
crosstalk: the example of the NT157 inhibitor. Oncogene. 2016 May
19;35(20):2562-4. doi: 10.1038/onc.2015.392. Epub 2015 Oct 19. PubMed PMID:
26477311.
2: Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K,
Levitzki A, Karin M. Targeting colorectal cancer via its microenvironment by
inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.
Oncogene. 2016 May 19;35(20):2634-44. doi: 10.1038/onc.2015.326. Epub 2015 Sep
14. PubMed PMID: 26364612; PubMed Central PMCID: PMC4791217.
3: Flashner-Abramson E, Klein S, Mullin G, Shoshan E, Song R, Shir A, Langut Y,
Bar-Eli M, Reuveni H, Levitzki A. Targeting melanoma with NT157 by blocking Stat3
and IGF1R signaling. Oncogene. 2016 May 19;35(20):2675-80. doi:
10.1038/onc.2015.229. Epub 2015 Jun 29. PubMed PMID: 26119932.
4: Garofalo C, Capristo M, Mancarella C, Reunevi H, Picci P, Scotlandi K.
Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma
Cell Lines. Front Endocrinol (Lausanne). 2015 May 13;6:74. doi:
10.3389/fendo.2015.00074. eCollection 2015. PubMed PMID: 26029165; PubMed Central
PMCID: PMC4429561.
5: Ibuki N, Ghaffari M, Reuveni H, Pandey M, Fazli L, Azuma H, Gleave ME,
Levitzki A, Cox ME. The tyrphostin NT157 suppresses insulin receptor substrates
and augments therapeutic response of prostate cancer. Mol Cancer Ther. 2014
Dec;13(12):2827-39. doi: 10.1158/1535-7163.MCT-13-0842. Epub 2014 Sep 29. PubMed
PMID: 25267499.
